China Summit Highlights: Real-world evidence, medtech and deals

Biotech leaders from three continents, Debra Yu, Henk Joos and David Oxley, discuss RWE, medtech, precision medicine and China’s role in global deals

LianBio’s Debra Yu, Agio Capital’s Henk Joos and Exopharm’s David Oxley join the BioCentury podcast team to discuss the key takeaways from the 8th annual China Healthcare Summit’s second day of sessions. Yu, Joos and Oxley discuss the importance of real-world evidence for drug development in China, China’s impact on the global medtech ecosystem and China biotech’s role in global dealmaking as seen from Australia, Belgium and the U.S.